Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
about
Novel approaches to target HER2-positive breast cancer: trastuzumab emtansineSpontaneous epithelial-mesenchymal transition and resistance to HER-2-targeted therapies in HER-2-positive luminal breast cancer.Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin) in HER2-overexpressing breast cancer cells.Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation.tabAnti-HER2 (erbB-2) oncogene effects of phenolic compounds directly isolated from commercial Extra-Virgin Olive Oil (EVOO)Data perturbation independent diagnosis and validation of breast cancer subtypes using clustering and patterns.Towards improved cancer diagnosis and prognosis using analysis of gene expression data and computer aided imaging.EGFR may couple moderate alcohol consumption to increased breast cancer risk.Boolean ErbB network reconstructions and perturbation simulations reveal individual drug response in different breast cancer cell lines.Widespread alternative exon usage in clinically distinct subtypes of Invasive Ductal CarcinomaTrastuzumab-induced recruitment of Csk-homologous kinase (CHK) to ErbB2 receptor is associated with ErbB2-Y1248 phosphorylation and ErbB2 degradation to mediate cell growth inhibition.A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer.The epidermal growth factor receptor family in breast cancer.Targeting the function of the HER2 oncogene in human cancer therapeutics.Identification of the YES1 Kinase as a Therapeutic Target in Basal-Like Breast CancersRedox potential ultrasensitive nanoparticle for the targeted delivery of camptothecin to HER2-positive cancer cells.Loss of Hsp90 association up-regulates Src-dependent ErbB2 activity.Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer.Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast CancerTarget points in trastuzumab resistanceDifferent mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation.Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas.The Therapeutic Challenge of Targeting HER2 in Endometrial CancerProtein tyrosine phosphatase SHP-1 sensitizes EGFR/HER-2 positive breast cancer cells to trastuzumab through modulating phosphorylation of EGFR and HER-2.Targeting HER2 Positive Breast Cancer with Chemopreventive Agents.Trastuzumab: a novel standard option for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancerBasal Protein Expression Is Associated With Worse Outcome and Trastuzamab Resistance in HER2+ Invasive Breast Cancer.Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signalingThe relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patientsCytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patientsCytomics - importance of multimodal analysis of cell function and proliferation in oncology.Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006Identification of Targetable ERBB2 Aberrations in Head and Neck Squamous Cell Carcinoma.Expression of Wnt3 activates Wnt/β-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells.Role of trastuzumab in the management of HER2-positive metastatic breast cancer.Presence of HER4 associates with increased sensitivity to Herceptin in patients with metastatic breast cancer.Generation, characterization, and maintenance of trastuzumab-resistant HER2+ breast cancer cell lines.Protein kinase A activation confers resistance to trastuzumab in human breast cancer cell lines.Efficacy of an EGFR-specific peptide against EGFR-dependent cancer cell lines and tumor xenografts.Influence of the HER receptor ligand system on sensitivity to cetuximab and trastuzumab in gastric cancer cell lines.
P2860
Q26747729-863D86B7-0AA3-4F3C-B554-59A1BC612C17Q31132069-4E89840F-1B77-4F18-B4DE-20215DFBF818Q33284158-8C8DB3DD-A0CE-40EE-AF5D-7795D3C46A76Q33291042-B1F88A6B-737C-4D4B-830A-9FD1B5DEADDDQ33394374-BEE3D8E9-89CC-4877-BE0A-3A40366E7428Q33449315-6E5731DB-E962-4C21-ABC4-274537EE2D20Q33459037-6B27F9E3-DDB6-45AC-A97B-D43B913A0799Q33858538-88B1DA67-596D-4501-A067-50D69D66B9AFQ33864932-6E4C6797-4A7A-4891-9637-7594AA7EFFB2Q33911898-8FE581D2-C3A6-4B25-B31D-2F8189A2C090Q33989927-F1D7B130-7580-466C-983A-87169645FAA2Q34077853-F85569A9-00EE-4E39-8AFC-B938451D7105Q34363400-EAEF335D-5F8B-4708-9D6F-4123F00FD321Q34766486-8D56C6CD-72F4-44E0-BA81-3018BB68F535Q34972623-F256B8F3-8B39-482F-980D-5EC995B5926DQ35100738-C0DF5A0A-37C6-4B8A-A797-EDEABB2A9DE2Q35641650-98F806B3-64E3-400C-8C6B-C297355B69D3Q35677713-2C038BE0-899C-4216-ABC2-4CAAD20385A4Q35684440-A2F2B108-E79E-40E2-AA1A-259DEFCCA280Q35821286-28EA7AB1-C206-4A8E-BE16-97760B56F96FQ35889621-DA171440-C8EA-4362-92F0-1736E08F3A60Q35889941-2B3BDE10-AD95-4A0F-BF20-0837614914CDQ36064912-8D1EA9E7-A8FC-4391-8E36-ABEC251E7B13Q36078326-BA487F48-E34A-4C02-90BD-1F30C70A3892Q36114852-BB568C17-4CA8-46CB-AD7D-90074A729FFFQ36220464-096531C0-950E-4A6B-A23E-17A6F20E9BBFQ36279794-3BB47624-A357-4515-BD72-5A68E9E16CF0Q36402698-D00ECFFE-1A61-4909-ADF2-45FD00FE758DQ36614287-8BCD0013-FF1C-4FBC-8E70-69A82D331B2AQ36643014-C37A638C-9A18-409B-A58C-021FB630BC7AQ36655213-92DB2152-7E68-47D4-BA62-13DBE401AEBCQ36810717-2D931D59-08AF-4285-9C52-5330C15C0BADQ37013995-10856FE8-3285-4A6A-B2BD-97899EACE3E9Q37066536-1121B8A1-E5FA-467F-A237-A203051F7D7FQ37355370-A9DC15E4-915A-4FD6-BF90-991261A6E47BQ37360194-C51E27CE-10BC-450D-9B59-94C7CBD543DCQ37447938-A92CD91E-2509-407C-9264-613B72B4D470Q37455274-DBBF0CAB-9413-42E5-BE9F-857090630F2BQ37689592-A92E21B0-15B0-4F8C-A473-5D27BB4AFF70Q37703226-BB0570D5-026B-4FD8-A157-660B36E7E71F
P2860
Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Epidermal growth factor recept ...... or interaction and activation.
@en
type
label
Epidermal growth factor recept ...... or interaction and activation.
@en
prefLabel
Epidermal growth factor recept ...... or interaction and activation.
@en
P2093
P1476
Epidermal growth factor recept ...... or interaction and activation.
@en
P2093
Ferdinand Hofstaedter
Gero Brockhoff
Gábor Horváth
János Szöllosi
Simone Diermeier
P304
P356
10.1016/J.YEXCR.2004.12.008
P407
P577
2005-01-21T00:00:00Z